Literature DB >> 22695157

Differences in virus prevalence and load in the hearts of patients with idiopathic dilated cardiomyopathy with and without immune-mediated inflammatory diseases.

Robert Dennert1, Pieter van Paassen, Petra Wolffs, Catrien Bruggeman, Sebastiaan Velthuis, Susanne Felix, Robert-Jan van Suylen, Harry J Crijns, Jan Willem Cohen Tervaert, Stephane Heymans.   

Abstract

Infections with cardiotrophic viruses and immune-mediated responses against the heart have been suggested to play a dominant role in the pathogenesis of idiopathic dilated cardiomyopathy (DCM). Furthermore, immune-mediated inflammatory diseases (IMIDs) may result in DCM. It has not previously been assessed whether DCM patients with and without an IMID have different prevalences and quantities of cardiotrophic viruses in the heart. Therefore, we compared the profiles of cardiotrophic viruses in heart tissue of DCM patients with and without an IMID. Serum and myocardial tissue samples were obtained from 159 consecutive patients with DCM and 20 controls. Patients were subdivided into three groups, the first two based on the presence (n = 34) or absence (n = 125) of an IMID and the third being a control group. The parvovirus B19 virus genome was detected in equal quantities in the non-IMID DCM patients (100/125) and the control group (15/20) but in lower quantities in the IMID patients (21/34, P = 0.02). Both the non-IMID and IMID DCM patients demonstrated increased myocardial inflammation compared to controls: 12.5 ± 1.8 and 14.0 ± 3.2 CD45-positive inflammatory cells, respectively, versus 5.1 ± 0.7 for the controls (P < 0.05 for both). Importantly, significantly higher parvovirus B19 copy numbers could be amplified in non-IMID than in IMID patients (561 ± 97 versus 191 ± 92 copies/μg DNA, P < 0.001) and control subjects (103 ± 47 copies/μg DNA, P < 0.001). The present study shows decreased parvovirus B19 prevalence and copy numbers in hearts of DCM patients with an IMID compared to those without an IMID. These findings may suggest that DCM patients with an IMID have a different pathophysiologic mechanism from that which is present in the virus-induced form of DCM.

Entities:  

Mesh:

Year:  2012        PMID: 22695157      PMCID: PMC3416102          DOI: 10.1128/CVI.00281-12

Source DB:  PubMed          Journal:  Clin Vaccine Immunol        ISSN: 1556-679X


  44 in total

1.  Circulating cardiac-specific autoantibodies as markers of autoimmunity in clinical and biopsy-proven myocarditis. The Myocarditis Treatment Trial Investigators.

Authors:  A L Caforio; J H Goldman; A J Haven; K M Baig; L D Libera; W J McKenna
Journal:  Eur Heart J       Date:  1997-02       Impact factor: 29.983

2.  Myocarditis: the Dallas criteria.

Authors:  H T Aretz
Journal:  Hum Pathol       Date:  1987-06       Impact factor: 3.466

3.  Viral persistence in the myocardium is associated with progressive cardiac dysfunction.

Authors:  Uwe Kühl; Matthias Pauschinger; Bettina Seeberg; Dirk Lassner; Michel Noutsias; Wolfgang Poller; Heinz-Peter Schultheiss
Journal:  Circulation       Date:  2005-09-19       Impact factor: 29.690

4.  Report of the 1995 World Health Organization/International Society and Federation of Cardiology Task Force on the Definition and Classification of cardiomyopathies.

Authors:  P Richardson; W McKenna; M Bristow; B Maisch; B Mautner; J O'Connell; E Olsen; G Thiene; J Goodwin; I Gyarfas; I Martin; P Nordet
Journal:  Circulation       Date:  1996-03-01       Impact factor: 29.690

5.  Circulating monocytes in patients with acute coronary syndromes lack sufficient interleukin-10 production after lipopolysaccharide stimulation.

Authors:  P L van Haelst; J W Cohen Tervaert; J Bijzet; C Baljé-Volkers; J F May; B Langeveld; R O B Gans
Journal:  Clin Exp Immunol       Date:  2004-11       Impact factor: 4.330

6.  Increased cardiac expression of tissue inhibitor of metalloproteinase-1 and tissue inhibitor of metalloproteinase-2 is related to cardiac fibrosis and dysfunction in the chronic pressure-overloaded human heart.

Authors:  Stephane Heymans; Blanche Schroen; Pieter Vermeersch; Hendrik Milting; Fangye Gao; Astrid Kassner; Hilde Gillijns; Paul Herijgers; Willem Flameng; Peter Carmeliet; Frans Van de Werf; Yigal M Pinto; Stefan Janssens
Journal:  Circulation       Date:  2005-08-15       Impact factor: 29.690

7.  A clinical trial of immunosuppressive therapy for myocarditis. The Myocarditis Treatment Trial Investigators.

Authors:  J W Mason; J B O'Connell; A Herskowitz; N R Rose; B M McManus; M E Billingham; T E Moon
Journal:  N Engl J Med       Date:  1995-08-03       Impact factor: 91.245

Review 8.  Defining criteria for autoimmune diseases (Witebsky's postulates revisited)

Authors:  N R Rose; C Bona
Journal:  Immunol Today       Date:  1993-09

9.  Soluble interleukin-2 receptor levels in patients with dilated cardiomyopathy. Correlation with disease severity and cardiac autoantibodies.

Authors:  C J Limas; I F Goldenberg; C Limas
Journal:  Circulation       Date:  1995-02-01       Impact factor: 29.690

Review 10.  Detection and monitoring of virus infections by real-time PCR.

Authors:  F Watzinger; K Ebner; T Lion
Journal:  Mol Aspects Med       Date:  2006-02-14
View more
  9 in total

1.  Predictors of outcome in patients with parvovirus B19 positive endomyocardial biopsy.

Authors:  Simon Greulich; Ingrid Kindermann; Julia Schumm; Andrea Perne; Stefan Birkmeier; Stefan Grün; Peter Ong; Tim Schäufele; Karin Klingel; Steffen Schneider; Reinhard Kandolf; Michael Böhm; Udo Sechtem; Heiko Mahrholdt
Journal:  Clin Res Cardiol       Date:  2015-07-02       Impact factor: 5.460

Review 2.  Meta-analysis on the immunohistological detection of inflammatory cardiomyopathy in endomyocardial biopsies.

Authors:  Julius L Katzmann; Peter Schlattmann; Angelos G Rigopoulos; Ewa Noutsias; Boris Bigalke; Matthias Pauschinger; Carsten Tschope; Daniel Sedding; P Christian Schulze; Michel Noutsias
Journal:  Heart Fail Rev       Date:  2020-03       Impact factor: 4.214

3.  Ron receptor-dependent gene regulation of Kupffer cells during endotoxemia.

Authors:  Rishikesh M Kulkarni; William D Stuart; Susan E Waltz
Journal:  Hepatobiliary Pancreat Dis Int       Date:  2014-06

4.  Silicone implant incompatibility syndrome (SIIS): a frequent cause of ASIA (Shoenfeld's syndrome).

Authors:  J W Cohen Tervaert; R M Kappel
Journal:  Immunol Res       Date:  2013-07       Impact factor: 2.829

Review 5.  Viral myocarditis: a prime example for endomyocardial biopsy-guided diagnosis and therapy.

Authors:  Sophie Van Linthout; Carsten Tschöpe
Journal:  Curr Opin Cardiol       Date:  2018-05       Impact factor: 2.161

6.  Telbivudine in chronic lymphocytic myocarditis and human parvovirus B19 transcriptional activity.

Authors:  Sophie Van Linthout; Ahmed Elsanhoury; Oliver Klein; Marzena Sosnowski; Kapka Miteva; Dirk Lassner; Mohamed Abou-El-Enein; Burkert Pieske; Uwe Kühl; Carsten Tschöpe
Journal:  ESC Heart Fail       Date:  2018-08-11

Review 7.  Systematic Review of PCR Proof of Parvovirus B19 Genomes in Endomyocardial Biopsies of Patients Presenting with Myocarditis or Dilated Cardiomyopathy.

Authors:  Angelos G Rigopoulos; Bianca Klutt; Marios Matiakis; Athanasios Apostolou; Sophie Mavrogeni; Michel Noutsias
Journal:  Viruses       Date:  2019-06-18       Impact factor: 5.048

8.  Clinical significance of chronic myocarditis: systematic review and meta-analysis.

Authors:  Keiichi Hirono; Shinya Takarada; Mako Okabe; Nariaki Miyao; Hideyuki Nakaoka; Keijiro Ibuki; Sayaka Ozawa; Hideki Origasa; Fukiko Ichida; Kyoko Imanaka-Yoshida
Journal:  Heart Vessels       Date:  2021-08-07       Impact factor: 2.037

Review 9.  Myocarditis and inflammatory cardiomyopathy: current evidence and future directions.

Authors:  Carsten Tschöpe; Enrico Ammirati; Biykem Bozkurt; Alida L P Caforio; Leslie T Cooper; Stephan B Felix; Joshua M Hare; Bettina Heidecker; Stephane Heymans; Norbert Hübner; Sebastian Kelle; Karin Klingel; Henrike Maatz; Abdul S Parwani; Frank Spillmann; Randall C Starling; Hiroyuki Tsutsui; Petar Seferovic; Sophie Van Linthout
Journal:  Nat Rev Cardiol       Date:  2020-10-12       Impact factor: 49.421

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.